A Promising Novel Treatment for Endometriosis

Maria Rosa Maduro
In: Reproductive Sciences · 2016 · vol. 23(9) , pp. 1121 · doi:10.1177/1933719116658401 · W3049077016
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This article reviews novel therapies targeting endometriosis, including rhTNFR:Fe, anti-interleukin 6 receptor monoclonal antibodies, and fenretinide, while also discussing the potential of statins.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This paper discusses endometriosis and highlights a set of emerging or “novel” therapeutic approaches, drawing on prior experimental and translational work, including targeted interventions such as immunomodulatory strategies (e.g., tocilizumab in animal models) and growth/signaling pathway inhibition (e.g., MAPK/VEGFR control with sorafenib). It also references mechanistic and integrative findings from endometriosis studies, alongside broader evidence syntheses like systematic reviews evaluating medication classes (e.g., statins) and related investigational agents (e.g., fenretinide). The main limitation stated implicitly by the format is that it is not a single new clinical trial but rather a perspective/overview grounded in heterogeneous prior literature. This paper is centrally about endometriosis — it focuses on promising novel treatment approaches for endometriosis by synthesizing prior preclinical and mechanistic evidence.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,000 characters · extracted from oa-doi-fallback · click to expand
Article PDF References Bulun S. Endometriosis. N Engl J Med. 2009;360(3):268–279. Liu Y, Sun L, Hou Z, Mao Y, Cui Y, Liu J. rhTNFR:Fe suppresses the development of endometriosis in a mouse model by downregulating cell proliferation and invasiveness. Reprod Sei. 2016;23(7):847–857. Taskin M, Gungor A, Adali E, Yay A, Onder G, Inceboz U. A humanized anti-interleukin 6 receptor monoclonal antibody, toci-lizumab, for the treatment of endometriosis in a rat model. Reprod Sei. 2016;23(5):662–669. Tosti C, Pinzauti S, Santulli P, Chapron C, Petraglia F. Pathogenetic mechanisms of deep infiltrating endometriosis. Reprod Sei. 2015;22(9):1053–1059. Leconte M, Santulli P, Chouzenoux S, et al. Inhibition of MAPK and VEGFR by sorafenib controls the progression of endometriosis. Reprod Sei. 2015;22(9):1171–1180. Yang H, Kang K, Cheng C, Mamillapalli R, Taylor H. Integrative analysis reveals regulatory programs in endometriosis. Reprod Sci. 2015;22(9):1060–1072. Zanatta A, Pereira R, Rocha A, et al. The relationship among HOXA10, estrogen reeeptor a, progesterone reeeptor, and pro-gesterone reeeptor B proteins in rectosigmoid endometriosis: a tissue microarray study. Reprod Sei. 2015;22(1):31–37. Vitagliano A, Noventa M, Quaranta M, Gizzo S. Statins as targeted “magical pills” for the conservative treatment of endometriosis:may potential adverse effects on female fertility represent the “dark side of the same coin”? A systematic review of literature. Reprod Sci. 2016;23(4):415–428. Taylor H, Osteen K, Bruner-Tran K, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814–823. Pavone M, Malpani S, Dyson M, Kim J, Bulun S. Fenretinide: a potential treatment for endometriosis. Reprod Sci. 2016;23(9):1139–1147. Rights and permissions About this article Cite this article Maduro, M.R. A Promising Novel Treatment for Endometriosis. Reprod. Sci. 23, 1121 (2016). https://doi.org/10.1177/1933719116658401 Published: Issue date: DOI: https://doi.org/10.1177/1933719116658401

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK